태아연골유래 세포를 이용한 면역질환의 예방 및 치료용 조성물
    61.
    发明授权
    태아연골유래 세포를 이용한 면역질환의 예방 및 치료용 조성물 有权
    用于预防或治疗包含人胎儿软骨衍生细胞的免疫疾病的组合物

    公开(公告)号:KR101536815B1

    公开(公告)日:2015-07-15

    申请号:KR1020130106091

    申请日:2013-09-04

    Abstract: 본발명은조직이식시 발생하는면역반응을억제/조절할수 있는태아연골유래세포를이용한면역질환예방또는치료용조성물에관한것으로, 보다상세하게는상기태아연골유래세포는면역반응을일으키지않고, 오히려활성화된림프구의증식을억제하고, 상기활성화림프구에서생성되는면역싸이토카인의발현을제어하는특성을지니고있고, 증식능력과다양한세포조직으로의분화능력이성체줄기세포에비해월등하여손상된조직의재생과함께이식시 발생할수 있는면역반응을조절할수 있는면역조절제로서유용하게사용할수 있다.

    태아연골유래 세포를 이용한 자가면역질환 또는 이식거부질환의 예방 및 치료용 조성물
    62.
    发明公开
    태아연골유래 세포를 이용한 자가면역질환 또는 이식거부질환의 예방 및 치료용 조성물 有权
    用于预防或治疗自身免疫性疾病或移植排斥的组合物,其包含人胎儿软骨来源的细胞

    公开(公告)号:KR1020150042755A

    公开(公告)日:2015-04-21

    申请号:KR1020150037356

    申请日:2015-03-18

    CPC classification number: A61K35/32 A61K9/0014 A61K9/0019

    Abstract: 본발명은조직이식시 발생하는면역반응을억제/조절할수 있는태아연골유래세포를이용한면역질환예방또는치료용조성물에관한것으로, 보다상세하게는상기태아연골유래세포는면역반응을일으키지않고, 오히려활성화된림프구의증식을억제하고, 상기활성화림프구에서생성되는면역싸이토카인의발현을제어하는특성을지니고있고, 증식능력과다양한세포조직으로의분화능력이성체줄기세포에비해월등하여손상된조직의재생과함께이식시 발생할수 있는면역반응을조절할수 있는면역조절제로서유용하게사용할수 있다.

    Abstract translation: 本发明涉及可以抑制/控制对组织移植的免疫应答的用于使用人胎儿软骨来源的细胞来预防或治疗免疫疾病的组合物。 更具体地,人胎儿软骨来源的细胞不引起免疫应答,而是抑制活化淋巴细胞的增殖,控制活化淋巴细胞中产生的免疫细胞因子的表达,并且具有更好的增殖和分化能力 细胞组织与成体干细胞相比较,因此可用于再生受损组织和用作控制对移植物的免疫应答的免疫控制剂。

    GP-GPU를 이용한 3D 의료 영상 정합의 병렬처리방법
    64.
    发明公开
    GP-GPU를 이용한 3D 의료 영상 정합의 병렬처리방법 有权
    GP-GPU并行处理三维医学图像注册

    公开(公告)号:KR1020140025639A

    公开(公告)日:2014-03-05

    申请号:KR1020120091184

    申请日:2012-08-21

    CPC classification number: G06T15/08 G06T3/40 G06T2200/04 G06T2207/30004

    Abstract: The present invention provides an adjustment technique of a medical image required to monitor diseases in the medical image obtained from a same patent at different times. According to the present invention, provided is a parallel processing method of a three-dimensional (3D) medical image adjustment using GP-GPU. The present invention is applied with parallel processing based on the GP-GPU in order to rapidly and accurately process 3D medical image data by gathering strengths of an existing division-based technique and a pixel-based technique. [Reference numerals] (AA) Input 2 volume; (BB) Scaling; (CC) Initialization step; (DD) Extract binary volume; (EE) Calculate the center; (FF) Calculate the principal axis of inertia; (GG) Optimization step; (HH) Convert floating volume; (II) Update P; (JJ) Is m_val minimum?; (KK) Optimize; (LL) Matched volume; (MM) P : Set of transformation parameters; (NN) m_val : Voxel similarity measurement value

    Abstract translation: 本发明提供了在不同时间从同一专利获得的医学图像中监测疾病所需的医疗图像的调整技术。 根据本发明,提供了使用GP-GPU的三维(3D)医学图像调整的并行处理方法。 本发明应用于基于GP-GPU的并行处理,以通过收集现有的基于分割的技术和基于像素的技术的优势来快速且准确地处理3D医学图像数据。 (附图标记)(AA)输入2音量; (BB)缩放; (CC)初始化步骤; (DD)提取二进制体积; (EE)计算中心; (FF)计算惯性主轴; (GG)优化步骤; (HH)转换浮动音量; (二)更新P; (JJ)是m_val最小? (KK)优化; (LL)匹配体积; (MM)P:变换参数集; (NN)m_val:体素相似度测量值

    태아연골조직유래 줄기세포원 및 이를 포함하는 세포치료제
    65.
    发明公开
    태아연골조직유래 줄기세포원 및 이를 포함하는 세포치료제 无效
    从胎盘组织和细胞治疗剂衍生的新型干细胞来源

    公开(公告)号:KR1020140016841A

    公开(公告)日:2014-02-10

    申请号:KR1020130090233

    申请日:2013-07-30

    Abstract: The present invention relates to a stem cell source derived from a fetal cartilage tissue and a cellular therapeutic agent comprising the same. The present invention relates to a development of a stem cell source using fetal tissue derived cells, which have less restriction in ethics than the existing known embryonic stem cell, facilitate the control of differentiation, and have more excellent proliferative performance and differentiating performance than adult stem cells. According to the present invention, the cells isolated from the fetal cartilage tissue express a surface antigen specific to embryonic stem cells, such as SSEA-4, and a transcription factor specific to embryonic stem cells, such as Oct4, and also express surface antigens of mesenchymal stem cells, such as Stro-1, CD29, CD90, and CD105. The cells derived from the fetal cartilage tissue are more excellent in the cell proliferative performance and the differentiating performance into various cell tissues than adult stem cells, and thus can be used as a new stem cell source for regenerating damaged tissues. Particularly, the cells derived from the fetal cartilage tissue were verified to form no tumors when being transplanted under the skin of immunosuppressive mice (nude mice), and can be transplanted in the human body at high safety.

    Abstract translation: 本发明涉及源自胎儿软骨组织的干细胞源和包含其的细胞治疗剂。 本发明涉及使用胎儿组织来源的细胞的干细胞来源的发展,其比现有已知的胚胎干细胞具有较少的伦理限制,促进分化的控制,并且具有比成体干细胞更优异的增殖性能和分化性能 细胞。 根据本发明,从胎儿软骨组织分离的细胞表达对胚胎干细胞(例如SSEA-4)特异性的表面抗原,以及对胚胎干细胞(例如Oct4)特异的转录因子,并且还表达表达抗原 间充质干细胞,如Stro-1,CD29,CD90和CD105。 来自胎儿软骨组织的细胞在细胞增殖性能和与各种细胞组织的分化性能方面比成体干细胞更优异,因此可以用作新的干细胞源用于再生受损组织。 特别地,当被移植到免疫抑制小鼠(裸鼠)的皮肤下时,来自胎儿软骨组织的细胞被证实不形成肿瘤,并且可以以高安全性移植到人体内。

    줄기세포 분화용 세포 자극 및 검출 바이오칩
    66.
    发明公开
    줄기세포 분화용 세포 자극 및 검출 바이오칩 失效
    细胞刺激的生物学和干细胞分化检测

    公开(公告)号:KR1020060134264A

    公开(公告)日:2006-12-28

    申请号:KR1020050053823

    申请日:2005-06-22

    CPC classification number: G01N33/5302 G01N2035/00158

    Abstract: A method for preparing a biochip of cell stimulation and detection is provided to obtain the chip capable of applying mechanical stimulation to cells and also detecting and observing it at the same time with a single chip, thereby being used for stem cell, and applied to tissue engineering, medicals and pharmaceuticals. The method for fabricating a cell stimulation and detection bio-chip comprises the steps of: (a) applying a micro-machining process to a lower substrate made of silicone, glass or polymer to form a micro-channel, a stimulation chamber, and a detection chamber; (b) fabricating an inlet and an outlet of a fluid on an upper substrate using an electrochemical discharge machining process; (c) connecting the upper substrate to the lower substrate; and (d) attaching a driver for mechanical stimulation thereto.

    Abstract translation: 提供了一种制备细胞刺激和检测生物芯片的方法,以获得能够对细胞施加机械刺激的芯片,并且同时用单个芯片进行检测和观察,从而用于干细胞,并应用于组织 工程,医疗和药品。 用于制造细胞刺激和检测生物芯片的方法包括以下步骤:(a)将微加工工艺应用于由硅树脂,玻璃或聚合物制成的下基板以形成微通道,刺激室和 检测室; (b)使用电化学放电加工工艺在上基板上制造流体的入口和出口; (c)将上基板连接到下基板; 和(d)附加用于机械刺激的驾驶员。

Patent Agency Ranking